# Royalty Pharma plc (RPRX) FY2024 Q3 Balance Sheet

- Company: Royalty Pharma plc (RPRX)
- Period: As of 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-11-06, accession number 0001802768-24-000058
- Page: https://plicit.ai/financials/rprx/fy2024-q3-balance-sheet
- Chart image: https://plicit.ai/charts/rprx-fy2024-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2024-09-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 18,042,242,000 US dollars
- **Current assets**: 1,794,195,000 US dollars
- **Non-current assets**: 16,248,047,000 US dollars
- **Liabilities**: 7,783,775,000 US dollars
- **Current liabilities**: 1,167,758,000 US dollars
- **Non-current liabilities**: 6,616,017,000 US dollars
- **Equity**: 10,258,467,000 US dollars
- **Noncontrolling interest**: 3,388,589,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Cash and cash equivalents**: 950,052,000 US dollars
- **Financial royalty assets**: 765,773,000 US dollars
- **Available for sale debt securities**: 48,500,000 US dollars
- **Other royalty income receivable**: 24,901,000 US dollars
- **Other current assets**: 4,969,000 US dollars
- **Financial royalty assets, net**: 14,968,074,000 US dollars
- **Available for sale debt securities**: 657,300,000 US dollars
- **Equity method investments**: 351,017,000 US dollars
- **Equity securities**: 228,867,000 US dollars
- **Other assets**: 42,789,000 US dollars
- **Current portion of long-term debt**: 996,942,000 US dollars
- **Distributions payable to legacy non-controlling interests**: 79,149,000 US dollars
- **Interest payable**: 38,412,000 US dollars
- **Other current liabilities**: 31,200,000 US dollars
- **Accounts payable and accrued expenses**: 22,055,000 US dollars
- **Long-term debt**: 6,610,437,000 US dollars
- **Other liabilities**: 5,580,000 US dollars
- **Additional paid-in capital**: 4,107,742,000 US dollars
- **Retained earnings**: 2,764,685,000 US dollars
- **Common stock - Class R Redeemable Shares**: 63,000 US dollars
- **Common stock - Class A Ordinary Shares**: 45,000 US dollars
- **Common stock - Class B Ordinary Shares**: 0 US dollars
- **Deferred shares, $0.000001 par value; issued and outstanding: 2024–390,502 and 2023–384,640**: 0 US dollars
- **Non-controlling interests**: 3,388,589,000 US dollars
- **Treasury interests**: negative 2,657,000 US dollars
- **Gross equity (calculated)**: 10,261,124,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.